Tumor-derived organoids have emerged as crucial tools in diagnosing and modeling primary liver cancers, particularly hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Among 39 studies analyzed, most organoids were patient-derived, showcasing their role in biomarker discovery and therapeutic exploration. Innovative approaches like organoid-on-a-chip systems suggest promising advancements in treatment regimens. These findings underline the importance of personalized therapy as organoids replicate the tumor microenvironment, thus facilitating the identification of biomarkers and therapeutic targets for precision medicine.
Journal Article by Qureshi AA, Wehrle CJ (…) Schlegel A et 15 al. in JHEP Rep
© 2024 The Authors.